Iovance Biotherapeutics


Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Industries

Employees

201-500

Links


Org chart

Frederick G. Vogt
Interim CEO, President & General Counsel
Collapse
Howard B. Johnson
Chief Business Officer
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
EVP, Human Resources
Kevin Smyth
EVP, Quality
Hequn Yin
SVP, Research
Stefanie Bulilan
Sr. Director Quality Systems And Compliance
Sean Rocca
Executive Counsel
Dan Kirby
Chief Commercial Officer (cco)
Sara Pellegrino
Svp, Investor Relations & Corporate Communications
Kun Wang
Senior Patent Counsel
Jonathan W.
Associate General Counsel
Matthew Rosinack
Senior Vice President Finance
Michele Fernandes
SVP Portfolio Management
Rana Fiaz M.d.
Executive Medical Director
Hana Sahdev
Senior Securities And Corporate Counsel

Board & advisors